<DOC>
	<DOCNO>NCT02978235</DOCNO>
	<brief_summary>The Phase 1 portion study determine safety TAS4464 appropriate dose patient Multiple Myeloma Lymphoma . The Phase 2 portion study investigate efficacy safety TAS4464 patient Multiple Myeloma Lymphoma</brief_summary>
	<brief_title>A Dose Finding Study Followed Safety Efficacy Study Patients With Multiple Myeloma Lymphoma</brief_title>
	<detailed_description>Background Rationale : • TAS4464 investigational NEDD8 activate enzyme ( NAE ) inhibitor , compound may affect cancer cell growth survival . Thus , TAS4464 may help treatment cancer . Phase 1 : Primary : - To investigate safety tolerability TAS4464 - To identify tolerate dose TAS4464 Secondary : - To investigate preliminary efficacy TAS4464 - To investigate pharmacokinetics ( PK ) pharmacogenomics ( PGx ) TAS4464 - To investigate pharmacodynamics TAS4464 Phase 2 : Primary : • To investigate efficacy TAS4464 Secondary : • To investigate safety profile TAS4464</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>1 . Provide write informed consent 2 . Women childbearing potential must negative pregnancy test Multiple Myeloma : Confirmed diagnosis Multiple Myeloma measurable disease , treat least two prior line therapy . Prior treatment must include proteasome inhibitor immunomodulatory agent , administer either separately combination , unless intolerance agent . Lymphoma : Confirmed diagnosis NonHodgkin Lymphoma measurable disease , treat least one anthracyclinebased therapy , relapse progression since last treatment receive . 1 . Any following treatment , within specify time frame , prior first dose TAS4464 : 1 . Major surgery within 28 day 2 . Radiation/chemotherapy within 21 day 3 . Monoclonal antibody within 28 day 4 . Corticosteroid administration &gt; 20 mg/day prednisone equivalent within 14 day 5 . Proteasome inhibitor within 14 day 6 . Immunomodulatory agent within 7 day 7 . Stem cell transplant within 3 month 8 . Current immunosuppressive treatment graft versus host disease 9 . Current use investigational agent 2 . Active graft versus host disease 3 . Known serious illness medical condition 4 . Prior treatment TAS4464 know hypersensitivity inactive ingredient drug similar class 5 . Pregnant breastfeed female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed/Refractory</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Non-Hodgkin Lymphoma</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>MCL</keyword>
	<keyword>Peripheral T-Cell Lymphoma</keyword>
	<keyword>PTCL</keyword>
	<keyword>TAS4464</keyword>
	<keyword>NEDD8</keyword>
	<keyword>NAE inhibitor</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Hematologic Diseases</keyword>
</DOC>